REG - Genflow Biosciences - Result of AGM

Genflow BiosciencesAnnouncement

27/06/2024 13:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240627:nRSa1943Ua&default-theme=true

RNS Number : 1943U  Genflow Biosciences PLC  27 June 2024

 

27 June 2024

Genflow Biosciences Plc

Results of Annual General Meeting

 

 

Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company")
an emerging leader in the field of longevity research, focused on developing
therapeutic solutions for the prevention of age-related diseases is pleased to
announce that all resolutions proposed at the Annual General Meeting held
earlier today were duly passed.

 

 

 Contacts

                                   Harbor Access

 Genflow Biosciences
 Dr Eric Leire, CEO                Jonathan Paterson, Investor Relations
 +32-477-495-881                   +1 475 477 9401
                                   Jonathan.Paterson@Harbor-access.com

 Capital Plus Partners Ltd
 Keith Swann, +44 0203 821 6169
 Jon Critchley, +44 0203 821 6168

 

About Genflow

Founded in 2020, Genflow Biosciences Plc. (LSE:GENF) (OTCQB:GENFF), a
biotechnology company headquartered in the UK with R&D facilities in
Belgium, is pioneering gene therapies to decelerate the aging process, with
the goal of promoting longer and healthier lives while mitigating the
financial, emotional, and social impacts of a fast-growing aging global
population. Genflow's lead compound, GF-1002, works through the delivery of a
centenarian variant of the SIRT6 gene which has yielded promising preclinical
results. Scheduled to begin in 2025, Genflow's clinical trial aims to explore
the potential benefits of GF-1002 in treating MASH (Metabolic
Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver
disease for which there is no effective treatments.

Please visit www.genflowbio.com (http://www.genflowbio.com) and follow the
Company on LinkedIn and Twitter/X.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGQKOBQDBKDAAB